Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit

Size: px
Start display at page:

Download "Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit"

Transcription

1 Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit R. M. Venn, 1 C. J. Bradshaw, 1 R. Spencer, 2 D. Brealey, 3 E. Caudwell, 3 C. Naughton, 4 A. Vedio, 4 M. Singer, 3 R. Feneck, 4 D. Treacher, 4 S. M. Willatts 2 and R. M. Grounds 1 1 Department of Intensive Care, St George s Hospital, Blackshaw Road, London SW17 0QT, UK 2 Department of Intensive Care, Bristol Royal Infirmary, Marlborough St, Bristol, UK 3 Department of Intensive Care, University College Hospital, Mortimer St, London, UK 4 Department of Intensive Care, St Thomas Hospital, Lambeth Palace Rd, London, UK Summary Dexmedetomidine, a highly selective and potent a 2 -adrenergic agonist, has a potentially useful role as a sedative agent in patients requiring intensive care. As part of a larger European multicentre trial, a total of 119 postoperative cardiac and general surgical patients requiring ventilation and sedation in an intensive care unit were enrolled in four centres in the United Kingdom. One hundred and five patients were randomly allocated to receive either dexmedetomidine or placebo with rescue sedation and analgesia provided by midazolam and morphine, respectively. Compared with the control group, intubated patients receiving dexmedetomidine required 80% less midazolam [mean 4.9 (5.8) mg.kg ¹1.h ¹1 vs (27.5) mg.kg ¹1.h ¹1,p< ], and 50% less morphine [11.2 (13.4) mg.kg ¹1.h ¹1 vs (19.4) mg.kg ¹1.h ¹1,p ¼ ]. Cardiovascular effects and adverse events could be predicted from the known properties of alpha-2 agonists. In conclusion, dexmedetomidine is a useful agent for the provision of postoperative analgesia and sedation. Keywords Dexmedetomidine; sedation. Intensive care; postoperative.... Correspondence to: Dr R. M. Grounds Accepted: 28 May 1999 Intubated, mechanically ventilated patients on the intensive care unit (ICU) require sedation and analgesia in order to tolerate the tracheal tube, artificial ventilation and other intensive care procedures such as bronchial suctioning, physiotherapy and catheter placement. Sedation may improve outcome by reducing the stress response and its sequelae to these interventions [1]. However, sedation regimens also have potentially adverse effects which may increase morbidity and prolong the clinical course [2]. Consequently, sedation techniques are changing and new drugs, working at different sites in the central nervous system to traditional agents, have been developed. Dexmedetomidine is a new, highly selective and potent a 2 -adrenoreceptor agonist under investigation as a sedative agent in intensive care patients. As well as offering sedation and anxiolysis, a 2 agonists have analgesic qualities and reduce the stress response to surgery and intensive care procedures [3]. Importantly, at therapeutic doses, dexmedetomidine does not cause any significant respiratory depression [4]. This paper reports the initial experience of this agent for postoperative sedation in four ICUs in the United Kingdom (UK). Methods Patients admitted postoperatively to general or cardiothoracic intensive care units at four teaching hospitals in the UK were enrolled into the study. Patients were aged 18 years or over and were expected to require a minimum of 6 h postoperative sedation and ventilation. Exclusion criteria were patients with serious central nervous system trauma or undergoing neurosurgery, a requirement for neuromuscular blocking agents, epidural or spinal anaesthesia, any contraindications or allergy to any of the trial drugs, gross obesity (over 50% above ideal body weight), admission for a drug overdose, prior enrolment in a trial Blackwell Science Ltd Amneal Pharmaceuticals LLC Exhibit 1024 Page 1136

2 R. M. Venn et al. Dexmedetomidine for postoperative sedation with any experimental drug in the last 30 days, uncontrolled diabetes and excessive bleeding which would be likely to require re-operation. Ethics committee approval was gained at each participating hospital and informed consent was obtained pre-operatively from each patient. Anaesthetic technique prior to entry into the ICU was left to the individual anaesthetist, the only constraint being that benzodiazepines were not used as sole anaesthetic agent. If remifentanil was used for intra-operative analgesia, morphine was given prior to leaving the operating theatre. The first four patients at each centre could be enrolled into an open label study to gain familiarity with dexmedetomidine. Data from these patients were included in the safety analysis. Subsequent patients were then entered into a randomised, double-blind, placebo-controlled trial on entry into the ICU. They received either placebo or dexmedetomidine, with midazolam and morphine used as clinically indicated for rescue sedation and analgesia, respectively. Both dexmedetomidine and placebo solutions were labelled study drug and coded for later analysis. Dexmedetomidine was supplied in 2-ml ampoules at a concentration of 100 mg.ml ¹1, and diluted with normal saline to a concentration of 4 mg.ml ¹1. Placebo solution (normal saline) was supplied and prepared in a similar fashion. Patients were randomly allocated on entry into the ICU to receive either dexmedetomidine or placebo, which was commenced within 1 h of arrival on the unit. The patients received a loading dose of 1 mg.kg ¹1 over 10 min followed by a maintenance infusion rate of mg.kg ¹1.h ¹1 into a peripheral or central vein. The sedation level of the patient was measured using the Ramsay Sedation Score [5] (Appendix A) and patients were maintained at a Ramsay sedation score greater than 2 whilst intubated. The infusion rate could be increased if this was not achieved or reduced if Ramsay sedation score 6 was reached. The protocol stipulated a maximum infusion rate of 0.7 mg.kg ¹1.h ¹1 ; bolus injections were not permitted. The patients were intubated and ventilated with oxygenenriched air to attain acceptable arterial blood gases for a minimum of 6 h. They were extubated when clinically indicated. Following extubation, the infusion was continued for a further 6 h and adjusted to achieve a Ramsay sedation score of more than 1. Sedation with the trial drug could be continued up to a total maximum duration of infusion of 24 h. If patients still required sedation and ventilation after 24 h, they were switched to the usual regimen used on each individual ICU. If adequate sedation was not achieved at the maximum study drug infusion rate, 0.02 mg.kg ¹1 midazolam boluses could be given intravenously. If more than three such boluses were required within 1 h, a midazolam infusion could be commenced (range mg.kg ¹1.h ¹1 ). Morphine could be administered for pain relief in 2-mg intravenous boluses as required, but not by continuous infusion. After extubation, paracetamol and morphine could be used as analgesic agents. Ramsay sedation scores were recorded hourly and prior to every infusion rate change, or prior to administration of midazolam. A further assessment was made at 10 min following each change. Total doses of midazolam, morphine and the study drug administered were recorded. Heart rate, arterial blood pressure, central venous blood pressure, respiratory rate and oxygen saturation were monitored continuously and recorded hourly for the duration of the study period and then at three-hourly intervals for 24 h after the infusion had ended. Temperature and arterial blood gases were recorded at regular intervals and a 12-lead electrocardiogram taken before and after the study infusion. Results are presented as mean (standard deviation (SD)). Analysis of variance for repeated measures was performed on haemodynamic parameters, with compensation for multiple post hoc comparisons using the Bonferroni correction. Intergroup statistical analyses were performed using the Mann Whitney U-test. Statistical significance was considered at p < Results Of the 119 patients recruited into the UK study, 14 patients entered the open-labelled study to receive dexmedetomidine and 105 patients were recruited into the double-blind randomised study. Seven of these 105 patients received less than 4 h study drug infusion as three returned to the operating theatre because of bleeding, two had bradycardia with hypotension, one had residual neuromuscular blockade and the other was withdrawn from the study at the surgeon s request because of operative complications. Details from these seven patients, plus those from the 14 patients entered into the open labelled study, were used only in the safety analysis. None of the patients in the open-labelled study were withdrawn because of complications. Of the 98 patients with complete data, 47 received dexmedetomidine (35 male, 12 female), and 51 received placebo (38 male, 13 female). Eighty-one patients (83%) underwent cardiac surgery requiring cardiopulmonary bypass, 39 of whom received dexmedetomidine. The remaining 17 patients underwent general, orthopaedic, head & neck, oncological or vascular surgery, of whom eight received dexmedetomidine. No differences were found between the groups with respect to age, sex, weight, height, operation time and intra-operative analgesia doses (Table 1) Blackwell Science Ltd 1137 Amneal Pharmaceuticals LLC Exhibit 1024 Page 1137

3 R. M. Venn et al. Dexmedetomidine for postoperative sedation Anaesthesia, 1999, 54, pages Table 1 Patient, anaesthetic and operative characteristics in the two groups (mean (SD)). Dexmedetomidine Placebo (n ¼ 47) (n ¼ 51) Age; years 63.3 (13.7) 64.2 (12.3) Weight; kg 76.3 (16.4) 75.9 (13.7) Male: Female 2.9: 1 2.9: 1 Duration of intubation; h 11.4 (4.9) 10.8 (5.8) Duration of study drug infusion; h 18.2 (4.6) 16.1 (4.4) Operation time; h 4.1 (1.1) 4.1(1.3) Intra-operative analgesia in morphine equivalents; mg 16.8 (13.4) 17.8 (10.0) Type of surgery 39 cardiac/8 general 42 cardiac/9 general Table 2 Midazolam requirements for the first 6 h of study and whilst intubated, followed by morphine requirements for the first 6 h, whilst intubated, whilst extubated and during observation period (mean (SD)). Dexmedetomidine Placebo (n ¼ 47) (n ¼ 51) p-value Midazolam 0 6h (mg.kg ¹1 ) 4.3 (5.8) 18.5 (24.6) 10 ¹3 < whilst intubated 4.9 (5.8) 23.7 (27.5) 10 ¹3 < Morphine 0 6h (mg.kg ¹1 ) 9.1 (9.6) 15.3 (17.4) 10 ¹ whilst intubated 11.2 (13.4) 21.5 (19.4) 10 ¹ whilst extubated 4.8 (11.0) 5.8 (5.5) 10 ¹ observation period 5.6 (10.6) 9.7 (17.7) 10 ¹3 ns There were no overall differences in the distribution of Ramsay sedation scores between the dexmedetomidine and placebo groups while intubated. However, intubated patients receiving dexmedetomidine required significantly less midazolam than those receiving placebo [4.9 (5.9) vs (27.5) mg.kg ¹1.h ¹1,p¼ ]. The requirement for morphine was reduced by half in the dexmedetomidine group while intubated [11.2 (13.4) vs (19.4) mg.kg ¹1.h ¹1,p¼ ], and by 17% after extubation [4.8 (11.0) vs. 5.8 (5.5) mg.kg ¹1.h ¹1,p¼ ] (Table 2). Those patients (n ¼ 9) on the higher infusion rates of dexmedetomidine ( mg.kg ¹1.h ¹1 )whilstintubated as compared with those (n ¼ 4) on the lowest infusion rates ( mg.kg ¹1.h ¹1 ) required more midazolam (9.3 (1.7) vs (0.58) mg.kg ¹1.h ¹1 ) and morphine (11.1 (3.2) vs. 4.3 (2.2) mg.kg ¹1.h ¹1 ) (Fig. 1). Six of the patients receiving placebo and 17 receiving dexmedetomidine required no midazolam while intubated. In addition, two on placebo and six receiving dexmedetomidine required no analgesia. All were cardiac surgical patients with no significant differences in their intra-operative analgesia, age or pathology. In general surgical patients, the placebo group required six times as much midazolam in the first 6 h compared with the dexmedetomidine group (p ¼ 0.02). Overall, morphine requirements in general surgical patients were twice those of cardiac surgical patients, irrespective of the method of sedation. Figure 1 Requirements for rescue sedation and analgesia at differing dexmedetomidine infusion rates. (B) Midazolam; (A) morphine Blackwell Science Ltd Amneal Pharmaceuticals LLC Exhibit 1024 Page 1138

4 R. M. Venn et al. Dexmedetomidine for postoperative sedation There were no significant differences in the duration of intubation (11.4 (4.9) h vs (5.8) h), nor the duration of weaning (3.4 (3.2) h vs. 3.1 (3.0) h) between the dexmedetomidine and placebo groups, respectively. The mean duration of infusion in the dexmedetomidine group was 18.2 h (range h). The mean infusion rate of dexmedetomidine during intubation was (0.15) mg.kg ¹1.h ¹1 and, after extubation, (0.08) mg.kg ¹1.h ¹1 (n ¼ 43 as four patients remained intubated for > 24 h). There were no significant differences in respiratory rates nor arterial oxygen saturations between the dexmedetomidine and placebo groups. Insufficient arterial blood gas samples were collected to provide evaluable data on oxygen and carbon dioxide tensions. In the general surgical subgroup, those receiving dexmedetomidine had lower, albeit nonsignificant, respiratory rates (14 (4.7) vs. 21 (7.2) breath.min ¹1,p¼ 0.08) at 2 h after extubation, with 2% higher pulse oximetry readings (98.1 (0.8) vs. 96 (1.9), p ¼ ). No differences were seen between the cardiac patient subgroups. During the first hour of study drug infusion, systolic and diastolic arterial blood pressures, and heart rates were significantly lower in patients receiving dexmedetomidine. Thereafter, these differences in blood pressure diminished but those patients receiving dexmedetomidine continued to have significantly lower heart rates at around 75 beat.min ¹1. This was well demonstrated for the period 4 h before and after extubation (75 (5.6) vs. 91 (6.5) beat.min ¹1, < ] (Fig. 2). Over this same period, the mean systolic and diastolic arterial pressures in the dexmedetomidine group were consistently slightly lower than placebo by 6 mmhg and 5 mmhg, respectively (both p ¼ 0.05), with a reduction in the variability of the systolic pressures (p ¼ 0.05). No significant differences were seen in central venous pressures. General surgical patients showed more pronounced cardiovascular differences with a 9-mmHg reduction in diastolic arterial pressure in the dexmedetomidine group (57 (7) vs. 66 (8) mmhg, p ¼ 0.03) and significant tachycardia in the placebo group (78 (6) vs. 101 (9) beat.min ¹1,p¼ 0.02) in the period around extubation (Fig. 3). Safety was examined in all 119 patients recruited, 66 of whom received dexmedetomidine. There were four deaths (three in the placebo group, one in the dexmedetomidine group) but none of these deaths was considered attributable to the study drug. Ten patients who received dexmedetomidine and nine receiving placebo had clinically significant ECG changes all these patients had undergone cardiac surgery (Table 3). Eighteen of the 66 patients receiving dexmedetomidine experienced significant hypotension (mean arterial pressure < 60 mmhg or > 30% fall from preinfusion values) Figure 2 Cardiovascular profiles of all patients (n ¼ 98) for 0 6 h and extubation 4 h. Mean (SD) arterial pressures and heart rates for the two groups. (B) Dexmedetomidine; (A) placebo. or bradycardia (< 50 beat.min ¹1 ). In 11 patients, this occurred during the loading dose period. This resulted in a temporary interruption of the infusion in three patients and withdrawal from the study in a further three. There was no difference in the use of vasoactive drugs between groups (Table 4). Loading dose hypertension was reported as an adverse event in six patients receiving dexmedetomidine and five patients on placebo. In the dexmedetomidine group, this was a transient event (less than 10 min) but hypertension was sustained in the placebo group (between 10 min and 4 h) Blackwell Science Ltd 1139 Amneal Pharmaceuticals LLC Exhibit 1024 Page 1139

5 R. M. Venn et al. Dexmedetomidine for postoperative sedation Anaesthesia, 1999, 54, pages Table 3 Adverse events excluding hypotension and/or bradycardia. Event Dexmedetomidine Placebo (n ¼ 66) (n ¼ 53) Death 1 3 Loading dose hypertension 6 5 Atrial fibrillation/tachyarrythmias 8 5 Postoperative bleeding 6 6 Stroke 0 3 Angina 1 1 Myocardial infarction 0 2 Nausea and vomiting 16 5 Flashing lights 2 0 ECG changes 10 9 Discussion Dexmedetomidine is the dextro-stereoisomer and active ingredient of medetomidine, an agent used for many years in veterinary anaesthesia. It is a highly selective a 2 agonist with an affinity eight times that of clonidine for the adrenoceptor (a 2 : a 1 ratio 1600 : 1) [3]. a 2 adrenoceptors can be found in the central nervous system, peripheral nerves and autonomic ganglia at presynaptic and postsynaptic sites. Stimulation of presynaptic a 2 receptors located in sympathetic nerve endings inhibits the release of noradrenaline. Activation of postsynaptic receptors by a 2 agonists in the CNS leads to inhibition of sympathetic activity, decreases in blood pressure and heart rate, and sedation, while binding of agonists to a 2 adrenoceptors in the spinal cord produces analgesia [3]. Peripheral a 2 receptors in blood vessels mediate vascular smooth muscle contraction and a rapid injection of a potent a 2 agonist can result in transient hypertension [6]. Dexmedetomidine is rapidly and extensively distributed to tissues with a distribution half-life of 5 min and elimination half-life of 2 3 h. It is extensively metabolised by phase one and phase two reactions in the liver and both urinary and faecal excretion are involved in elimination of dexmedetomidine and its metabolites (Personal communication. Abbott Laboratories, Abbott Park, IL, USA). Although dexmedetomidine inhibits cytochrome P450 metabolism in the laboratory, clinically relevant drug interactions at the plasma concentrations found in humans are not expected [7]. Unlike etomidate, dexmedetomidine has negligible effects on adrenal steroidogenesis in dogs [8]. The principal end-points of the study were to see if there were any differences in midazolam and morphine requirements between postoperative patients receiving dexmedetomidine and placebo. This was clearly demonstrated by an 80% reduction in midazolam and a 50% reduction in morphine requirements. While intubated, 36% of patients Figure 3 General surgical patients cardiovascular profile (n ¼ 17) for 0 6 h and extubation 4 h. Mean (SD) arterial pressures and heart rates for the two groups. (B) Dexmedetomidine; (A) placebo. on dexmedetomidine and 11% on placebo required no midazolam. The placebo-controlled nature of the protocol ultimately meant that the initial method of sedation differed between patients receiving dexmedetomidine and placebo. The dexmedetomidine group received a loading dose followed by an infusion of the sedative agent, whereas the placebo group received a loading dose followed by an infusion of placebo and so initially remained sedated under the influence of their intra-operative anaesthesia. On waking, they received midazolam boluses, sometimes followed by an infusion. Consequently, this made interpretation of the results difficult, especially during the first hour of the study, due to the less fluent Blackwell Science Ltd Amneal Pharmaceuticals LLC Exhibit 1024 Page 1140

6 R. M. Venn et al. Dexmedetomidine for postoperative sedation Table 4 Cardiovascular adverse events in 18/66 patients receiving dexmedetomidine. Arterial pressure Heart rate (mmhg) (beat.min ¹1 ) Outcome and treatment Loading dose events Hypotension 75/40 Infusion stopped after 10 min Bradycardia 45 Paced after 30 min and infusion stopped Hypotension 56/35 Infusion interrupted for 10 min Hypotension 70/41 Infusion interrupted for 42 min, restarted at reduced rate Hypotension 84/44 Resolved in 10 min with fluids & reduced infusion rate Hypotension 73/35 Resolved with fluids after 10 min Hypotension 95/56 Resolved with fluids within 30 min Hypotension 65/29 50 Paced after 20 min of infusion for 15 h Hypotension 77/40 45 Paced after 1 h of infusion for 7 h Bradycardia 79/40 52 Paced after 10 min of infusion for 12 h Hypotension 81/56 Resolved with fluids within 10 min Events at other times Bradycardia after 3 h of infusion 68/30 45 Atropine, inotropes & infusion stopped Bradycardia, repeated episodes 60/ Atropine & inotropes, infusion stopped after 20 h Hypotension & bradycardia after 11 h 75/54 48 Infusion interrupted for 2 h, fluids given Hypotension after 1 h 85/47 Hypotension resolved with fluids within 1 h Bradycardia, after 4 h 76/44 44 Resolved with fluids within 1 h of infusion Bradycardia, repeated episodes Resolved after 2 h, fluids only Bradycardia after 2 h of infusion 55 Resolved after 1 h, no treatment required sedation received by the placebo group. This may have accounted for the higher initial arterial blood pressures seen in the placebo group. The majority of adverse events (hypotension and bradycardia) occurred early in the study period as a result of the loading dose of dexmedetomidine; these were not a feature in the placebo group. This was predictable from the known properties of a 2 agonists and might have been avoided by omitting the loading dose and commencing the infusion while in the operating theatre. The protocol allowed neither boluses of study drug nor exceeding the maximum infusion rate (0.7 mg.kg ¹1.h ¹1 dexmedetomidine) if the patient lightened and required additional sedation. This may have accounted for some of the midazolam dosing used in the dexmedetomidine group. The maximum dexmedetomidine infusion rate was predetermined from Phase II clinical trials and was clearly insufficient in some patients (n ¼ 9). Patients receiving the maximum infusion rate required considerably more midazolam and, of interest, morphine requirements did not mirror midazolam, perhaps demonstrating that there is an analgesic ceiling-effect to dexmedetomidine. Future studies need to address these issues. The delay mentioned above in achieving an initial fluency of sedation may also have contributed to the cardiovascular differences seen between the groups. Cardiovascular data relating to the 4-h period before and after extubation are likely to be more representative of the differences between the groups. During this period, significant reductions were seen in heart rate, and systolic and diastolic arterial pressures in the dexmedetomidine group, resulting in a lower rate pressure product and, potentially, less ischaemic events due to reduced oxygen demand [9]. An obvious advantage of dexmedetomidine, in contrast to other sedation agents used to blunt cardiovascular responses in the peri-extubation period, is the reported lack of respiratory depression [10]. The hypotension and bradycardia occurring during the loading dose phase of the dexmedetomidine was only seen in cardiac patients. This is probably directly attributable to stimulation of the central postsynaptic a 2 receptors causing inhibition of sympathetic activity or augmentation of parasympathetic activity. Although dexmedetomidine is potentially a hypertensive agent by its peripheral a 2 vasoconstricting effect on vascular smooth muscle, no differences were seen between the two groups. Previous studies in healthy volunteers suggest this to be a transient event with overall dominance of the central effects [6]. The incidence of nausea and vomiting requiring an antiemetic was higher in patients receiving dexmedetomidine; this was contrary to previous findings in women undergoing minor gynaecological surgery [11]. The anxiolytic properties of dexmedetomidine were clearly demonstrated by the general surgical patients who were free from the effects of cardiac anaesthesia and bypass. This group had better pulse oximetry saturations (p ¼ 0.04), less tachycardia (p ¼ 0.04) and less tachypnoea (p ¼ 0.08)at extubation and up to 4 h afterwards. Although an increase in oxygen saturation of only 2% may not seem clinically significant, in combination with a lower respiratory rate 1999 Blackwell Science Ltd 1141 Amneal Pharmaceuticals LLC Exhibit 1024 Page 1141

7 R. M. Venn et al. Dexmedetomidine for postoperative sedation Anaesthesia, 1999, 54, pages (up to 33% lower), and a lower heart rate (up to 25%), this does have significant implications for potential reductions in fatigue and myocardial ischaemia, recognised hazards at the stressful time around extubation. The study was performed as part of a larger European Phase III trial and allowed up to four patients in each centre to be entered into an open label study so that medical staff could experience the unique nature of sedation with dexmedetomidine. Patients are calmly and easily roused from sleep to allow excellent communication and co-operation while intubated and ventilated, and then similarly quickly return to sleep. Complex tasks, such as communication by pen and paper, are possible. Nursing staff and patient questionnaires, although limited, revealed no significant differences in the ease of management of the patient, or the patient s memory of their time on intensive care. However, a small number of patients who received dexmedetomidine resented their increased level of awareness while on the ICU and found the whole experience very stressful, despite the apparent ease with which they were managed by ICU staff. Dexmedetomidine at the doses used may lack the amnesic properties of midazolam and this warrants further investigation. The study has shown that dexmedetomidine significantly reduces the requirements for rescue sedation and analgesia in a placebo-controlled trial in postoperative patients for up to 24 h. Its sedative properties differ from traditional agents with patients being more easily roused. Further trials are needed for direct comparisons to be made with traditional sedation agents, to establish its suitability in nonsurgical patients and for long-term use. Declaration This study was supported by Abbott Laboratories. Dr R. M. Grounds performs consultancy work on their behalf. The results of this study were presented in part at the 19th International Symposium on Intensive Care and Emergency Medicine, Brussels, References 1 Beattie WS, Buckley DN, Forrest JB. Epidural morphine reduces the risk of postoperative myocardial ischaemia in patients with cardiac risk factors. Canadian Journal of Anaesthesia 1993; 40: Prielipp RC, Coursin DB, Wood KE, Murray MJ. Complications associated with sedative and neuromuscular blocking drugs in critically ill patients. Critical Care Clinics 1995; 11: Hayashi Y, Maze M. Alpha-2 adrenoceptor agonists and anaesthesia. British Journal of Anaesthesia 1993; 71: Belleville JP, Ward DS, Bloor BC, et al. Ventilatory effects of dexmedetomidine in humans. Anesthesiology 1990; 73: A Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxolone alphadolone. British Medical Journal 1974; II: Bloor BC, Ward DS, Belleville JP, Maze M. Sedative and hemodynamic effects of dexmedetomidine in humans. Anesthesiology 1990; 73: A Dyck JB, Maze M, Shafer SL. The pharmacokinetics of dexmedetomidine in adults. Anesthesiology 1991; 75: A Maze M, Virtanen R, Daunt D, Banks SJ, Stover EP, Feldman D. Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: in vivo and in vitro studies. Anesthesia and Analgesia 1991; 73: Low JM. Haemodynamic monitoring. In: Oh TE, ed. Intensive Care Manual, 3rd edn. London: Butterworths, 1991: Conti J, Smith D. Haemodynamic responses to extubation after cardiac surgery with and without continued sedation. British Journal of Anaesthesia 1998; 80: Aantaa R, Kanto J, Scheinin M, Kallio A, Scheinin H. Dexmedetomidine an alpha 2 adrenoceptor agonist, reduces anaesthetic requirements for patients undergoing minor gynaecological surgery. Anesthesiology 1990; 73: Appendix A Level 1 Level 2 Level 3 Level 4 Level 5 Level 6 Patient awake, anxious and agitated or restless, or both Patient awake, co-operative, orientated, and tranquil Patient awake, responds to commands only Patient asleep, brisk response to light glabellar tap or loud auditory stimulus Patient asleep, sluggish response to light glabellar tap or loud auditory stimulus Patient asleep, no response to light glabellar tap or loud auditory stimulus Blackwell Science Ltd Amneal Pharmaceuticals LLC Exhibit 1024 Page 1142

Dexmedetomidine. Dr.G.K.Kumar,M.D.,D.A., Assistant Professor, Madras medical college,chennai. History

Dexmedetomidine. Dr.G.K.Kumar,M.D.,D.A., Assistant Professor, Madras medical college,chennai. History Dexmedetomidine Dr.G.K.Kumar,M.D.,D.A., Assistant Professor, Madras medical college,chennai Dexmedetomidine is the most recently released IV anesthetic. It is a highly selective α 2 -adrenergic agonist

More information

Dexmedetomidine vs. Propofol for Short-Term Sedation of Postoperative Mechanically Ventilated Patients

Dexmedetomidine vs. Propofol for Short-Term Sedation of Postoperative Mechanically Ventilated Patients Journal of the Egyptian Nat. Cancer Inst., Vol. 16, No. 3, September: 153-158, 2004 Dexmedetomidine vs. for Short-Term Sedation of Postoperative Mechanically Ventilated Patients SAMIA ELBARADIE, M.D.*;

More information

ASMIC 2016 DEXMEDETOMIDINE IN THE INTENSIVE CARE UNIT DR KHOO TIEN MENG

ASMIC 2016 DEXMEDETOMIDINE IN THE INTENSIVE CARE UNIT DR KHOO TIEN MENG ASMIC 2016 DEXMEDETOMIDINE IN THE INTENSIVE CARE UNIT DR KHOO TIEN MENG PREAMBLE : EVOLUTION OF SEDATION IN THE ICU 1980s : ICU sedation largely extension of GA No standard approach, highly variable Deep

More information

Susan Becker DNP, RN, CNS, CCRN, CCNS Marymount University, Arlington, VA

Susan Becker DNP, RN, CNS, CCRN, CCNS Marymount University, Arlington, VA Susan Becker DNP, RN, CNS, CCRN, CCNS Marymount University, Arlington, VA Disclosures Study and presentation has no commercial bias or interests No financial relationship with a commercial interest, products,

More information

PDF of Trial CTRI Website URL -

PDF of Trial CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Sun, 10 Mar 2019 06:52:14 GMT) CTRI Number Last Modified On 29/07/2016 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

Premedication with alpha-2 agonists procedures for monitoring anaesthetic

Premedication with alpha-2 agonists procedures for monitoring anaesthetic Vet Times The website for the veterinary profession https://www.vettimes.co.uk Premedication with alpha-2 agonists procedures for monitoring anaesthetic Author : Lisa Angell, Chris Seymour Categories :

More information

Study the Effect of Dexmedetomidine on Emergence Agitation after Nasal Surgeries

Study the Effect of Dexmedetomidine on Emergence Agitation after Nasal Surgeries Original Research Article Study the Effect of Dexmedetomidine on Emergence Agitation after Nasal Surgeries G V Krishna Reddy 1*, S. Kuldeep 2, G. Obulesu 3 1 Assistant Professor, Department of Anaesthesiology,

More information

Alfaxan. (alfaxalone 10 mg/ml) Intravenous injectable anesthetic for use in cats and dogs. TECHNICAL NOTES DESCRIPTION INDICATIONS

Alfaxan. (alfaxalone 10 mg/ml) Intravenous injectable anesthetic for use in cats and dogs. TECHNICAL NOTES DESCRIPTION INDICATIONS Alfaxan (alfaxalone 10 mg/ml) Intravenous injectable anesthetic for use in cats and dogs. NADA 141-342, Approved by FDA ALFAXAN (Schedule: C-IV) (alfaxalone 10 mg/ml) Intravenous injectable anesthetic

More information

Appendix: Outcomes when Using Adjunct Dexmedetomidine with Propofol Sedation in

Appendix: Outcomes when Using Adjunct Dexmedetomidine with Propofol Sedation in SUPPLEMENTAL CONTENT Appendix: Outcomes when Using Adjunct Dexmedetomidine with Propofol Sedation in Mechanically Ventilated Surgical Intensive Care Patients Table of Contents Methods Summary of Definitions

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Xylacare 2% w/v Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances Qualitative composition

More information

Pain Management in Racing Greyhounds

Pain Management in Racing Greyhounds Pain Management in Racing Greyhounds Pain Pain is a syndrome consisting of multiple organ system responses, and if left untreated will contribute to patient morbidity and mortality. Greyhounds incur a

More information

A Clinical Study of Dexmedetomidine under Combined Spinal Epidural Anaesthesia at a Tertiary Care Hospital

A Clinical Study of Dexmedetomidine under Combined Spinal Epidural Anaesthesia at a Tertiary Care Hospital Original Research A Clinical Study of Dexmedetomidine under Combined Spinal Epidural Anaesthesia at a Tertiary Care Hospital Kamala GR 1, Leela GR 2 1 Assistant Professor, Department of Anaesthesiology,

More information

Propofol vs Dexmedetomidine

Propofol vs Dexmedetomidine Propofol vs Dexmedetomidine A highlight of similarities & differences Lama Nazer, PharmD, BCPS Critical Care Clinical Pharmacy Specialist King Hussein Cancer Center Outline Highlight similarities and differences

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NOSEDORM 5 mg/ml Solution for injection for dogs and cats [DE, ES, FR, PT] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each

More information

Hemodynamic effects of dexmedetomidine-- fentanyl vs. nalbuphine--propofol in plastic surgery

Hemodynamic effects of dexmedetomidine-- fentanyl vs. nalbuphine--propofol in plastic surgery Hemodynamic effects of dexmedetomidine-- fentanyl vs. nalbuphine--propofol in plastic surgery Juan F. De la Mora-González *, José A. Robles-Cervantes 2,4, José M. Mora-Martínez 3, Francisco Barba-Alvarez

More information

Dıfferent Doses Of Dexmedetomidine On Controllıng Haemodynamıc Responses To Tracheal Intubatıon

Dıfferent Doses Of Dexmedetomidine On Controllıng Haemodynamıc Responses To Tracheal Intubatıon ISPUB.COM The Internet Journal of Anesthesiology Volume 27 Number 2 Dıfferent Doses Of Dexmedetomidine On Controllıng Haemodynamıc Responses To Tracheal Intubatıon A Sa??ro?lu, M Celik, Z Orhon, S Yüzer,

More information

A comparison of dexmedetomidine and midazolam for sedation in third molar surgery*

A comparison of dexmedetomidine and midazolam for sedation in third molar surgery* doi:10.1111/j.1365-2044.2007.05230.x A comparison of dexmedetomidine and midazolam for sedation in third molar surgery* C. W. Cheung, 1 C. L. A. Ying, 2 W. K. Chiu, 3 G. T. C. Wong, 1 K. F. J. Ng 4 and

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Dormilan solution for injection for dogs and cats [FR] Dormilan 1 mg/ml solution for injection for dogs and cats [DE, ES,

More information

A New Advancement in Anesthesia. Your clear choice for induction.

A New Advancement in Anesthesia. Your clear choice for induction. A New Advancement in Anesthesia Your clear choice for induction. By Kirby Pasloske When using Alfaxan, patients should be continuously monitored, and facilities for maintenance of a patent airway, artificial

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Medeson 1 mg/ml solution for injection for dogs and cats [AT, CY, CZ, DE, EL, ES, HR, IT, LT, LV, PL, PT, RO, SI, SK] Medeson,

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Domitor 1 solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Medetomidine hydrochloride (equivalent

More information

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT PACKAGE LEAFLET FOR: Dormilan solution for injection for dogs and cats [FR] Dormilan 1 mg/ml solution for injection for dogs and cats [DE, PT, UK] Reanest 1 mg/ml solution for injection for dogs and cats

More information

Haemodynamic and anaesthetic advantages of dexmedetomidine

Haemodynamic and anaesthetic advantages of dexmedetomidine Haemodynamic and anaesthetic advantages of dexmedetomidine Abstract Rao SH, Assistant Professor Sudhakar B, Associate Professor Subramanyam PK, Professor Department of Anaesthesia and Critical Care, Dr

More information

Study between clonidine and dexmedetomidine in attenuation of pressor response during endotracheal intubation

Study between clonidine and dexmedetomidine in attenuation of pressor response during endotracheal intubation Original Research Article Study between clonidine and dexmedetomidine in attenuation of pressor response during endotracheal intubation K. Selvarju 1, Kondreddi Narayana Prasad 2*, Ajay Kumar Reddy Bobba

More information

Day 90 Labelling, PL LABELLING AND PACKAGE LEAFLET

Day 90 Labelling, PL LABELLING AND PACKAGE LEAFLET LABELLING AND PACKAGE LEAFLET A. LABELLING PARTICULARS TO APPEAR ON THE OUTER PACKAGE : Carton 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Alvegesic vet. 10 mg/ml Solution for injection for Horses, Dogs

More information

Role of Dexmedetomidine as an Anesthetic Adjuvant in Laparoscopic Surgery

Role of Dexmedetomidine as an Anesthetic Adjuvant in Laparoscopic Surgery Role of Dexmedetomidine as an Anesthetic Adjuvant in Laparoscopic Surgery Vaishali Waindeskar, Munir Khan, Shankar Agarwal, M R Gaikwad Department of Anesthesiology, People s College of Medical Sciences

More information

SCIENTIFIC COOPERATIONS MEDICAL WORKSHOPS July, 2015, Istanbul - TURKEY

SCIENTIFIC COOPERATIONS MEDICAL WORKSHOPS July, 2015, Istanbul - TURKEY 21-22 July, 2015, Istanbul - TURKEY PROSPECTIVE EVALUATION OF CORRELATION OF DEPTH OF DEXMEDETOMIDINE SEDATION AND CLINICAL EFFECTS FOR RECONSTRUCTIVE SURGERIES UNDER REGIONAL ANAESTHESIA Alma Jaunmuktane

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Intravenous Dexmedetomidine Premedication on Spinal Anaesthesia with Hyperbaric Bupivacaine

More information

Comparison of Intensive Care Unit Sedation Using Dexmedetomidine, Propofol, and Midazolam

Comparison of Intensive Care Unit Sedation Using Dexmedetomidine, Propofol, and Midazolam Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/24 Comparison of Intensive Care Unit Sedation Using Dexmedetomidine, Propofol, and Midazolam Gajendra Singh, Kakhandki

More information

Comparison of dexmedetomidine v/s propofol used as adjuvant with combined spinal epidural anaesthesia for joint replacement surgeries

Comparison of dexmedetomidine v/s propofol used as adjuvant with combined spinal epidural anaesthesia for joint replacement surgeries Comparison of dexmedetomidine v/s propofol used as adjuvant with combined spinal epidural anaesthesia for joint replacement surgeries Kuldeep Chittora 1 *; Ritu Sharma 2 ; Rajeev LochanTiwari 3 1 Department

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. Name of the Veterinary Medicinal Product Vetofol 10mg/ml Emulsion for Injection for cats and dogs (AT, CY, EE, FI, DE, EL, LV, PT, ES) Norofol 10mg/ml Emulsion for

More information

Use of Dexmedetomidine for Sedation of Children Hospitalized in the Intensive Care Unit

Use of Dexmedetomidine for Sedation of Children Hospitalized in the Intensive Care Unit ORIGINAL RESEARCH Use of Dexmedetomidine for Sedation of Children Hospitalized in the Intensive Care Unit Christopher L. Carroll, MD 1 Diane Krieger, MSN, CPNP 1 Margaret Campbell, PharmD 2 Daniel G. Fisher,

More information

DOI /yydb medetomidine a review of clinical applications J. Curr Opin Anaesthesiol

DOI /yydb medetomidine a review of clinical applications J. Curr Opin Anaesthesiol 1573 medetomidine a review of clinical applications J. Curr Opin Anaesthesiol 2008 21 4 457-461. 6 DAHMANI S PARIS A JANNIER V et al. Dexmedetom- 2. α 2 idine increases hippocampal phosphorylated extracellular

More information

What dose of methadone should I use?

What dose of methadone should I use? What dose of methadone should I use? Professor Derek Flaherty BVMS, DVA, DipECVAA, MRCA, MRCVS RCVS and European Specialist in Veterinary Anaesthesia SPC dose rates for Comfortan dogs: 0.5-1.0 mg/kg SC,

More information

Comparison of anesthesia with a morphine lidocaine ketamine infusion or a morphine lidocaine epidural on time to extubation in dogs

Comparison of anesthesia with a morphine lidocaine ketamine infusion or a morphine lidocaine epidural on time to extubation in dogs Veterinary Anaesthesia and Analgesia, 2016, 43, 86 90 doi:10.1111/vaa.12273 SHORT COMMUNICATION Comparison of anesthesia with a morphine lidocaine ketamine infusion or a morphine lidocaine epidural on

More information

Quality of MRI pediatric sedation: Comparison between intramuscular and intravenous dexmedetomidine

Quality of MRI pediatric sedation: Comparison between intramuscular and intravenous dexmedetomidine Egyptian Journal of Anaesthesia (2013) 29, 47 52 Egyptian Society of Anesthesiologists Egyptian Journal of Anaesthesia www.elsevier.com/locate/egja www.sciencedirect.com Research Article Quality of MRI

More information

COMPARATIVE STUDY OF INTRAVENOUS DEXMEDETOMIDINE PLUS INTRATHECAL BUPIVACAINE VS INTRATHECAL BUPIVACAINE ALONE FOR PROLONGATION OF SPINAL ANALGESIA

COMPARATIVE STUDY OF INTRAVENOUS DEXMEDETOMIDINE PLUS INTRATHECAL BUPIVACAINE VS INTRATHECAL BUPIVACAINE ALONE FOR PROLONGATION OF SPINAL ANALGESIA COMPARATIVE STUDY OF INTRAVENOUS DEXMEDETOMIDINE PLUS INTRATHECAL BUPIVACAINE VS INTRATHECAL BUPIVACAINE ALONE FOR PROLONGATION OF SPINAL ANALGESIA H. L. Rani 1, I. Upendranath 2 1Associate Professor,

More information

A COMPARATIVE STUDY OF MIDAZOLAM, PROPOFOL AND DEXMEDETOMIDINE INFUSIONS FOR SEDATION IN ME- CHANICALLY VENTILATED PATIENTS IN ICU

A COMPARATIVE STUDY OF MIDAZOLAM, PROPOFOL AND DEXMEDETOMIDINE INFUSIONS FOR SEDATION IN ME- CHANICALLY VENTILATED PATIENTS IN ICU ORIGINAL ARTICLE A COMPARATIVE STUDY OF MIDAZOLAM, PROPOFOL AND DEXMEDETOMIDINE INFUSIONS FOR SEDATION IN ME- CHANICALLY VENTILATED PATIENTS IN ICU Suresh Chandra Dulara 1, Pooja Jangid 2, Ashish Kumar

More information

Original Article INTRODUCTION. Abstract

Original Article INTRODUCTION. Abstract Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2016/305 Comparison between 0.5 µg/kg Dexmedetomidine with 0.5% Lignocaine and 0.5% Lignocaine Alone in Intravenous for

More information

DISSOCIATIVE ANESTHESIA

DISSOCIATIVE ANESTHESIA DISSOCIATIVE ANESTHESIA Adarsh Kumar Dissociative anesthesia implies dissociation from the surrounding with only superficial sleep mediated by interruption of neuronal transmission from unconscious to

More information

Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care ²

Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care ² British Journal of Anaesthesia 88 (5): 669±75 (2002) Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care ² R. M. Venn 1*, M. D. Karol 2 and R.

More information

N.C. A and T List of Approved Analgesics 1 of 5

N.C. A and T List of Approved Analgesics 1 of 5 1 of 5 Note to user: This list of commonly used analgesics and sedatives is not all-inclusive. The absence of an agent does not necessarily mean it is unacceptable. For any questions, call the Clinical

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Narcostart 1 mg/ml solution for injection for cats and dogs (NL, AT, BE, CZ, EL, HU, IS, LU, PL, SK)

SUMMARY OF PRODUCT CHARACTERISTICS. Narcostart 1 mg/ml solution for injection for cats and dogs (NL, AT, BE, CZ, EL, HU, IS, LU, PL, SK) SUMMARY OF PRODUCT CHARACTERISTICS Revised: September 2015 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Narcostart 1 mg/ml solution for injection for cats and dogs (NL, AT, BE, CZ, EL, HU, IS, LU, PL, SK)

More information

Cheung, CW; Ying, CLA; Chiu, WK; Wong, GTC; Ng, KFJ; Irwin, MG

Cheung, CW; Ying, CLA; Chiu, WK; Wong, GTC; Ng, KFJ; Irwin, MG Title A comparison of dexmedetomidine and midazolam for sedation in third molar surgery Author(s) Citation Cheung, CW; Ying, CLA; Chiu, WK; Wong, GTC; Ng, KFJ; Irwin, MG 11th International Dental Congress

More information

The Effects of 2-Adrenergic Receptor Agonist Dexmedetomidine on Hemodynamic Response in Direct Laryngoscopy

The Effects of 2-Adrenergic Receptor Agonist Dexmedetomidine on Hemodynamic Response in Direct Laryngoscopy The Open Otorhinolaryngology Journal, 2007, 1, 5-11 5 The Effects of 2-Adrenergic Receptor Agonist Dexmedetomidine on Hemodynamic Response in Direct Laryngoscopy Berrin I ik, Mustafa Arslan *, Özgür Özsoylar

More information

Synopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets

Synopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study

More information

Comparison of dexmedetomidine and propofol in mechanically ventilated patients with sepsis: A pilot study

Comparison of dexmedetomidine and propofol in mechanically ventilated patients with sepsis: A pilot study Original article Comparison of dexmedetomidine and propofol in mechanically ventilated patients with sepsis: A pilot study Mark B. Sigler MD, Ebtesam A. Islam MD PhD, Kenneth M. Nugent MD Abstract Objective:

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Butomidor 10 mg/ml - Solution for injection for horses, dogs and cats SPC_labelling_PIL 22 December 2011 [Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL

More information

Dr. PratekKoolwal, Dr.BribalBaj, DrKashif M Madani, Dr.MohitSomani, Dr. Vijay Mathur.

Dr. PratekKoolwal, Dr.BribalBaj, DrKashif M Madani, Dr.MohitSomani, Dr. Vijay Mathur. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-853, p-issn: 2279-861.Volume 14, Issue 7 Ver. VIII (July. 215), PP 84-9 www.iosrjournals.org "Dose related prolongation of hyperbaric

More information

Procedure # IBT IACUC Approval: December 11, 2017

Procedure # IBT IACUC Approval: December 11, 2017 IACUC Procedure: Anesthetics and Analgesics Procedure # IBT-222.04 IACUC Approval: December 11, 2017 Purpose: The purpose is to define the anesthetics and analgesics that may be used in mice and rats.

More information

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents

Antibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique

More information

Study of efficacy and safety of intravenous Dexmedetomidine infusion as an adjuvant to Bupivacaine spinal anaesthesia in Abdominal hysterectomy

Study of efficacy and safety of intravenous Dexmedetomidine infusion as an adjuvant to Bupivacaine spinal anaesthesia in Abdominal hysterectomy ORIGINAL ARTICLE Study of efficacy and safety of intravenous Dexmedetomidine infusion as an adjuvant to Bupivacaine spinal anaesthesia in Abdominal hysterectomy Darshna Patel 1 *, Abdulrazak Saiyad 2,

More information

Australian and New Zealand College of Veterinary Scientists. Fellowship Examination. Veterinary Anaesthesia and Critical Care Paper 1

Australian and New Zealand College of Veterinary Scientists. Fellowship Examination. Veterinary Anaesthesia and Critical Care Paper 1 Australian and New Zealand College of Veterinary Scientists Fellowship Examination June 2016 Veterinary Anaesthesia and Critical Care Paper 1 Perusal time: Twenty (20) minutes Time allowed: Three (3) hours

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Acecare 2mg/ml Solution for Injection for Dogs and Cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains

More information

12/3/14. Top 10 Tips You Need to Know About for Anesthesia & Analgesia. Sponsorship. Introduction. VETgirl on the RUN!

12/3/14. Top 10 Tips You Need to Know About for Anesthesia & Analgesia. Sponsorship. Introduction. VETgirl on the RUN! Top 10 Tips You Need to Know About for Anesthesia & Analgesia Sponsorship Introduction Introduction Introduction VETgirl on the RUN! 1 Subscription plans Download our podcasts on itunes! Find us on social

More information

Module C Veterinary Anaesthesia Small Animal Anaesthesia and Analgesia (C-VA.1)

Module C Veterinary Anaesthesia Small Animal Anaesthesia and Analgesia (C-VA.1) Module C Veterinary Anaesthesia Small Animal Anaesthesia and Analgesia (C-VA.1) Module Leader - Elizabeth Armitage-Chan MA Vet MB DipACVA MRCVS RCVS Specialist in Veterinary Anaesthesia The aim of the

More information

Dexmedetomidine and stress response Madhusudan et al

Dexmedetomidine and stress response Madhusudan et al Original Article: Effect of intravenous dexmedetomidine on haemodynamic responses to laryngoscopy, tracheal intubation and anaesthetic and analgesic requirements: a randomized double-blind clinical efficacy

More information

Irish Medicines Board

Irish Medicines Board IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA:10778/003/002 Case No: 7003735 The Irish Medicines Board in exercise of the powers

More information

Australian College of Veterinary Scientists Fellowship Examination. Veterinary Anaesthesia and Critical Care Paper 1

Australian College of Veterinary Scientists Fellowship Examination. Veterinary Anaesthesia and Critical Care Paper 1 Australian College of Veterinary Scientists Fellowship Examination June 2011 Veterinary Anaesthesia and Critical Care Paper 1 Perusal time: Twenty (20) minutes Time allowed: Three (3) hours after perusal

More information

A comparison of the effectiveness of dexmedetomidine versus propofol target-controlled infusion for sedation during fibreoptic nasotracheal intubation

A comparison of the effectiveness of dexmedetomidine versus propofol target-controlled infusion for sedation during fibreoptic nasotracheal intubation doi:10.1111/j.1365-2044.2009.06226.x ORIGINAL ARTICLE A comparison of the effectiveness of dexmedetomidine versus propofol target-controlled infusion for sedation during fibreoptic nasotracheal intubation

More information

A SYSTEMATIC REVIEW ON THE USE OF DEXMEDETOMIDINE AS A SOLE AGENT FOR INTRAVENOUS MODERATE SEDATION

A SYSTEMATIC REVIEW ON THE USE OF DEXMEDETOMIDINE AS A SOLE AGENT FOR INTRAVENOUS MODERATE SEDATION A SYSTEMATIC REVIEW ON THE USE OF DEXMEDETOMIDINE AS A SOLE AGENT FOR INTRAVENOUS MODERATE SEDATION by Dr. Samuel Y. Toong A thesis submitted in conformity with the requirements for the degree of Master

More information

Rajaclimax Kirubahar, Bose Sundari, Vijay Kanna*, Kanakasabai Murugadoss

Rajaclimax Kirubahar, Bose Sundari, Vijay Kanna*, Kanakasabai Murugadoss International Journal of Research in Medical Sciences Kirubahar R et al. Int J Res Med Sci. 2016 Apr;4(4):1172-1176 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20160804

More information

Effective dose of dexmedetomidine to induce adequate sedation in elderly patients under spinal anesthesia

Effective dose of dexmedetomidine to induce adequate sedation in elderly patients under spinal anesthesia KJA Korean Journal of Anesthesiology Clinical Research Article pissn 2005-6419 eissn 2005-7563 Effective dose of dexmedetomidine to induce adequate sedation in elderly patients under spinal anesthesia

More information

Neonates and infants undergoing radiological imaging

Neonates and infants undergoing radiological imaging Dexmedetomidine for Pediatric Sedation for Computed Tomography Imaging Studies Keira P. Mason, MD* Steven E. Zgleszewski, MD* Jennifer L. Dearden, MD* Raymond S. Dumont, MD* Michele A. Pirich, RN, BSN

More information

Study of Dexmedetomidine as intramuscular premedication in outpatient cataract surgery: A placebo controlled study

Study of Dexmedetomidine as intramuscular premedication in outpatient cataract surgery: A placebo controlled study Original Research Article Study of Dexmedetomidine as intramuscular premedication in outpatient cataract surgery: A placebo controlled study D. Srinivasa Naik 1, K. Ravi Kumar 1, Surendra Babu 2, R. Pandu

More information

Original Article Effects of low dose midazolam on bradycardia and sedation during dexmedetomidine infusion

Original Article Effects of low dose midazolam on bradycardia and sedation during dexmedetomidine infusion Int J Clin Exp Med 2016;9(6):11838-11844 www.ijcem.com /ISSN:1940-5901/IJCEM0020616 Original Article Effects of low dose midazolam on bradycardia and sedation during dexmedetomidine infusion Yun-Sic Bang

More information

Dexmedetomidine and its Injectable Anesthetic-Pain Management Combinations

Dexmedetomidine and its Injectable Anesthetic-Pain Management Combinations Back to Anesthesia/Pain Management Back to Table of Contents Front Page : Library : ACVC 2009 : Anesthesia/Pain Management : Dexmedetomidine Dexmedetomidine and its Injectable Anesthetic-Pain Management

More information

Dexmedetomidine use in a pediatric cardiac intensive care unit: Can we use it in infants after cardiac surgery?

Dexmedetomidine use in a pediatric cardiac intensive care unit: Can we use it in infants after cardiac surgery? Cardiac Intensive Care Dexmedetomidine use in a pediatric cardiac intensive care unit: Can we use it in infants after cardiac surgery? Constantinos Chrysostomou, MD; Joan Sanchez De Toledo, MD; Tracy Avolio,

More information

Alfaxan FAQs. Repeatable. Reliable. Relax.

Alfaxan FAQs. Repeatable. Reliable. Relax. Alfaxan FAQs INDICATIONS: Alfaxan is indicated for the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic, in cats and dogs. Important

More information

Candidate Name: PRACTICAL Exercise Medications & Injections

Candidate Name: PRACTICAL Exercise Medications & Injections PRACTICAL Exercise Medications & Injections VERY IMPORTANT Method: In groups - staggered - PLEASE WAIT YOUR TURN / STAND BACK IF ASKED Do bookwork - work out dosages - 1a / 2a / 3a Got to Medications Table

More information

Feline blood transfusions: preliminary considerations

Feline blood transfusions: preliminary considerations Vet Times The website for the veterinary profession https://www.vettimes.co.uk Feline blood transfusions: preliminary considerations Author : Andrea Harvey Categories : RVNs Date : September 1, 2011 ABSTRACT

More information

THE EFFECTS OF MIDAZOLAM AND DEXMEDETOMIDINE INFUSION ON Peri-OPERATIVE ANXIETY IN REGIONAL ANESTHESIA

THE EFFECTS OF MIDAZOLAM AND DEXMEDETOMIDINE INFUSION ON Peri-OPERATIVE ANXIETY IN REGIONAL ANESTHESIA THE EFFECTS OF MIDAZOLAM AND DEXMEDETOMIDINE INFUSION ON Peri-OPERATIVE ANXIETY IN REGIONAL ANESTHESIA Elif Şenses *, Alparslan Apan **, Emıne Arzu Köse ***, Gökşen Öz *** and Hatice Rezaki **** Abstract

More information

Associate Professor, Department of Anaesthesiology, Government Thoothukudi Medical College, Thoothukudi, Tamil Nadu, India, 2

Associate Professor, Department of Anaesthesiology, Government Thoothukudi Medical College, Thoothukudi, Tamil Nadu, India, 2 Original Article DOI: 10.17354/ijss/2016/295 Effect of Intravenous use of Dexmedetomidine on Anesthetic Requirements in Patients Undergoing Elective Spine Surgery: A Double Blinded Randomized Controlled

More information

Ashraf Darwish, Rehab Sami, Mona Raafat, Rashad Aref and Mohamed Hisham

Ashraf Darwish, Rehab Sami, Mona Raafat, Rashad Aref and Mohamed Hisham Dexmedetomidine versus Propofol for Monitored Anesthesia Care In Patients Undergoing Anterior Segment Ophthalmic Surgery Under Peribulbar Medial Canthus Anesthesia Ashraf Darwish, Rehab Sami, Mona Raafat,

More information

Clinical applicability of dexmedetomidine for sedation, premedication and analgesia in cats 1 / 2007

Clinical applicability of dexmedetomidine for sedation, premedication and analgesia in cats 1 / 2007 1 / 2007 Clinical applicability of dexmedetomidine for sedation, premedication and analgesia in cats 1 5 Dexmedetomidine: a new 2-adrenoceptor agonist for modern multimodal anaesthesia in dogs and cats

More information

Intraoperative Sedation During Epidural Anesthesia: Dexmedetomidine Vs Midazolam

Intraoperative Sedation During Epidural Anesthesia: Dexmedetomidine Vs Midazolam ISPUB.COM The Internet Journal of Anesthesiology Volume 17 Number 2 Intraoperative Sedation During Epidural Anesthesia: Dexmedetomidine Vs Midazolam M Celik, N Koltka, B Cevik, H Baba Citation M Celik,

More information

Total Intravenous Anaesthesia (TIVA) in Veterinary Practice

Total Intravenous Anaesthesia (TIVA) in Veterinary Practice Total Intravenous Anaesthesia (TIVA) in Veterinary Practice Rukmani Dewangan 1, S. K. Tiwari 2 1, 2 Department of Veterinary Surgery and Radiology, College of Veterinay Science and A.H. Anjora Durg (C.G.),

More information

Non-invasive, mildly to moderately painful, procedures and examinations which require restraint, sedation and analgesia in dogs and cats.

Non-invasive, mildly to moderately painful, procedures and examinations which require restraint, sedation and analgesia in dogs and cats. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Sedadex 0.1 mg/ml solution for injection for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active substance: Dexmedetomidine hydrochloride

More information

Period of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)

Period of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit) Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's

More information

Therapeutics and clinical risk management (2011) Vol.7:291~299. Dexmedetomidine hydrochloride as a long-term sedative.

Therapeutics and clinical risk management (2011) Vol.7:291~299. Dexmedetomidine hydrochloride as a long-term sedative. Therapeutics and clinical risk management (2011) Vol.7:291~299. Dexmedetomidine hydrochloride as a long-term sedative Kunisawa Takayuki Therapeutics and Clinical Risk Management open access to scientific

More information

AUSTRALIAN PRODUCT INFORMATION DEXMEDETOMIDINE EVER PHARMA dexmedetomidine (as hydrochloride) 100 microgram/ml concentrated injection

AUSTRALIAN PRODUCT INFORMATION DEXMEDETOMIDINE EVER PHARMA dexmedetomidine (as hydrochloride) 100 microgram/ml concentrated injection AUSTRALIAN PRODUCT INFORMATION DEXMEDETOMIDINE EVER PHARMA dexmedetomidine (as hydrochloride) 100 microgram/ml concentrated injection 1 NAME OF THE MEDICINE Dexmedetomidine hydrochloride 2 QUALITATIVE

More information

DATA SHEET PRECEDEX 1. PRODUCT NAME 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 3. PHARMACEUTICAL FORM

DATA SHEET PRECEDEX 1. PRODUCT NAME 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 3. PHARMACEUTICAL FORM DATA SHEET PRECEDEX 1. PRODUCT NAME PRECEDEX (Dexmedetomidine hydrochloride) (100 micrograms/ml). The active ingredient in PRECEDEX is dexmedetomidine as hydrochloride. 2. QUALITATIVE AND QUANTITATIVE

More information

CERTIFICATE IN VETERINARY ANAESTHESIA

CERTIFICATE IN VETERINARY ANAESTHESIA WEDNESDAY 28 JULY 2004 PAPER l Candidates are required to answer ALL TEN questions. Allow 12 minutes per question. 1. Briefly describe the local analgesic technique you would use to permit dehorning of

More information

RETRACTED. Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery

RETRACTED. Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery Journal of Clinical Anesthesia (2006) 18, 422 426 Original contribution Dexmedetomidine infusion is associated with enhanced renal function after thoracic surgery Robert J. Frumento MS, MPH, Helene G.

More information

Corresponding author: V. Dua, Department of Anaesthesia, BJ Wadia Hospital for Children, Parel, Mumbai, India.

Corresponding author: V. Dua, Department of Anaesthesia, BJ Wadia Hospital for Children, Parel, Mumbai, India. Comparative evaluation of dexmedetomidine as a premedication given intranasally vs orally in children between 1 to 8 years of age undergoing minor surgical procedures V. Dua, P. Sawant, P. Bhadlikar Department

More information

NIH Public Access Author Manuscript J Crit Care. Author manuscript; available in PMC 2013 July 28.

NIH Public Access Author Manuscript J Crit Care. Author manuscript; available in PMC 2013 July 28. NIH Public Access Author Manuscript Published in final edited form as: J Crit Care. 2009 December ; 24(4): 568 574. doi:10.1016/j.jcrc.2009.05.015. A new dosing protocol reduces dexmedetomidine-associated

More information

PAIN Effect of intra-articular dexmedetomidine on postoperative analgesia after arthroscopic knee surgery

PAIN Effect of intra-articular dexmedetomidine on postoperative analgesia after arthroscopic knee surgery British Journal of Anaesthesia 101 (3): 395 9 (2008) doi:10.1093/bja/aen184 Advance Access publication June 20, 2008 PAIN Effect of intra-articular dexmedetomidine on postoperative analgesia after arthroscopic

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Narketan-10 100 mg/ml Solution for Injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance

More information

Critical appraisal Randomised controlled trial questions

Critical appraisal Randomised controlled trial questions Critical appraisal Randomised controlled trial questions Korpivaara, M., Laapas, K., Huhtinen, M., Schoning, B., Overall, K. (2017) Dexmedetomidine oromucosal gel for noise-associated acute anxiety and

More information

Review Article The Effects of Intravenous Dexmedetomidine Injections on IOP in General Anesthesia Intubation: A Meta-Analysis

Review Article The Effects of Intravenous Dexmedetomidine Injections on IOP in General Anesthesia Intubation: A Meta-Analysis Hindawi BioMed Research International Volume 7, Article ID 68683, 6 pages https://doi.org/.55/7/68683 Review Article The Effects of Intravenous Injections on IOP in General Anesthesia Intubation: A Meta-Analysis

More information

T u l a n e U n i v e r s i t y I A C U C Guidelines for Rodent & Rabbit Anesthesia, Analgesia and Tranquilization & Euthanasia Methods

T u l a n e U n i v e r s i t y I A C U C Guidelines for Rodent & Rabbit Anesthesia, Analgesia and Tranquilization & Euthanasia Methods T u l a n e U n i v e r s i t y I A C U C Guidelines for Rodent & Rabbit Anesthesia, Analgesia and Tranquilization & Euthanasia Methods Abbreviations: General Considerations IV = intravenous SC = subcutaneous

More information

Comparison of two doses of intranasal dexmedetomidine as premedication in children

Comparison of two doses of intranasal dexmedetomidine as premedication in children Comparison of two doses of intranasal dexmedetomidine as premedication in children V. Pavithra, M. N. Ramani, S. K. Shah Department of Anaesthesia, B. J. Medical College, Civil Hospital, Ahmedabad, Gujarat,

More information

Anesthetic regimens for mice, rats and guinea pigs

Anesthetic regimens for mice, rats and guinea pigs Comparative Medicine SOP #: 101. 01 Page: 1 of 10 Anesthetic regimens for mice, rats and guinea pigs The intent of the Standard Operating Procedure (SOP) is to describe commonly used methods to anaesthetize

More information

the same safe, reliable sedation and analgesia as DEXDOMITOR. specifically made for cats that weigh 7 lb or less.

the same safe, reliable sedation and analgesia as DEXDOMITOR. specifically made for cats that weigh 7 lb or less. feline dosing chart DEXDOMITOR 0.1 mg/ml (dexmedetomidine) Sedation/analgesia in cats Feline 40 mcg/kg IM lb kg ml 2 4 1 2 4.1 7 2.1 3 0.5 1.0 For higher weight ranges, use DEXDOMITOR (dexmedetomidine),

More information

Perioperative Pain Management in Veterinary Patients

Perioperative Pain Management in Veterinary Patients Perioperative Pain Management in Veterinary Patients Doris H. Dyson, DVM, DVSc KEYWORDS Analgesia Surgical pain Dog Cat As veterinarians in the twenty-first century, we have an ethical responsibility to

More information

Original Contributions

Original Contributions Original Contributions Use of Dexmedetomidine to Facilitate Extubation in Surgical Intensive-Care-Unit Patients Who Failed Previous Weaning Attempts Following Prolonged Mechanical Ventilation: A Pilot

More information

Review of local guidelines Contributes to CQC Regulation number: 9,11

Review of local guidelines Contributes to CQC Regulation number: 9,11 Dexmedetomidine Infusions in Burns Intensive Care for Adults Clinical Guideline Register No: 15026 Status: Public Developed in response to: Best practice Review of local guidelines Contributes to CQC Regulation

More information

Efficacy of dexmedetomidine in reducing postoperative morphine consumption in patients undergoing total abdominal hysterectomy

Efficacy of dexmedetomidine in reducing postoperative morphine consumption in patients undergoing total abdominal hysterectomy Original Article Brunei Int Med J. 2016; 12 (3): 97-103 Efficacy of dexmedetomidine in reducing postoperative morphine consumption in patients undergoing total abdominal hysterectomy Mazlilah ABDUL MALEK

More information

Comparison of Clonidine and Dexmedetomidine on Cardiovascular Stability in Laparoscopic Cholecystectomy

Comparison of Clonidine and Dexmedetomidine on Cardiovascular Stability in Laparoscopic Cholecystectomy Original Article DOI: 10.17354/ijss/2016/185 Comparison of Clonidine and Dexmedetomidine on Cardiovascular Stability in Laparoscopic Cholecystectomy Devang Bharti 1, Juhi Saran 2, Chetan Kumar 3, H S Nanda

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DEXDOMITOR 0.1 mg/ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Excipients:

More information